CG Oncology
CGON
195 hedge funds and large institutions have $3.43B invested in CG Oncology in 2025 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 72 increasing their positions, 50 reducing their positions, and 20 closing their positions.
151% more call options, than puts
Call options by funds: $74M | Put options by funds: $29.6M
115% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 20
44% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 50
11% more funds holding
Funds holding: 176 → 195 (+19)
10% more capital invested
Capital invested by funds: $3.13B → $3.43B (+$303M)
8% more funds holding in top 10
Funds holding in top 10: 12 → 13 (+1)
0.6% more ownership
Funds ownership: 101.84% → 102.44% (+0.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$76.7M |
| 2 |
State Street
Boston,
Massachusetts
|
+$39.3M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
+$31.9M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$20.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$58.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$56.8M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$43.8M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
-$27.1M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$25.2M |
CGON Hedge Fund Activity: Q4 2025 in Review
195 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in CG Oncology (CGON) for Q4 2025, worth a combined $3.43B — up 9.7% from $3.13B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new CGON positions and 20 closed out — a net gain of 23 holders — while 72 added to existing stakes and 50 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $76.7M. The largest seller was Braidwell, cutting an estimated $58.5M.
- 195 institutional investors held CG Oncology (CGON) as of Q4 2025, up from 176 in Q3 2025.
- Funds reported $3.43B of CG Oncology stock for Q4 2025, up 9.7% quarter-over-quarter.
- 43 funds opened new CG Oncology positions in Q4 2025 and 20 closed out, a net change of +23 holders.
- The largest CG Oncology buyer in Q4 2025 was T. Rowe Price Associates, an estimated $76.7M added.
- The largest CG Oncology seller in Q4 2025 was Braidwell, an estimated $58.5M sold.
Based on aggregated 13F filings for Q4 2025.